NETRF is proud to announce a two-year, $1 million grant from the Goldhirsh-Yellin Foundation. This significant gift will support research into the cause and treatment of neuroendocrine tumors. "We are pleased to donate to NETRF to support promising research focusing on the understanding of NETs," said Susan Grinel, PhD, Philanthropy Advisor for the Goldhirsh-Yellin Foundation.

The new grant will make it possible to advance our understanding of intestinal neuroendocrine tumors. “We are excited to have the Goldhirsh-Yellin Foundation as a long-standing partner in the search for cures for neuroendocrine cancer,” said Elyse Gellerman, NETRF CEO.  It is through the generosity of this foundation and other major donors that NETRF can fund innovative research leading us to better treatments and ultimately cures for NETs.”

The heartbreaking passing of the Queen of Soul, Aretha Franklin sparked worldwide attention not only within the music industry but also within the cancer community. Ms. Franklin was one of 177,000 Americans living with a neuroendocrine tumor. A third of those patients have a pancreatic neuroendocrine diagnosis, the specific type of cancer Aretha Franklin managed for nearly a decade. Since her cause of death was widely reported as pancreatic cancer, not neuroendocrine cancer, we ask for your help in raising awareness about the nature of NETs.We invite you to take action and support us in our quest for a cure. We've received several gifts honoring Aretha - since her passing and there is still time to give toward this effort. Gifts will fund pancreatic NET research. (MORE)

463 Walnut Road
North Yarmouth, ME
October 27, 7 -10 am
Sponsored by North Yarmouth Fire Company

(MORE)

Arlington, VA
November 10, 10 am
Sponsored by eGlobalTech

(MORE)